Injectable Influenza Vaccine

ic group). The formula for the 2027-2028 season shall be determined by the U.S. Food & Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee. Other specification data is included in the solicitation. Successful contractor must have FDA Approval, and the vaccine must be U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommended. National Stock Numbers shall be established at the time of award. An indefinite quantity contract is proposed. The quantity indicated is an annual estimate only. The guaranteed minimum will be 75% of the annual estimate, and a contract maximum will be established at 150% of the annual estimate. All quantities shall be delivered to the Defense Depot New Cumberland, PA. The contractor shall be capable of delivering 40% of the requirement by August 12, 2027, 25% by August 26, 2027, 25% by September 9, 2027, and the residual 10% by September 23, 2027. This delivery schedule is the preferred delivery schedule. Other delivery schedules may be considered. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and SAM.gov at https://www.sam.gov. Interested parties should contact Rosbert Jones (445-737-1254) (Rosbert.Jones@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of presolicitation or solicitation changes through this website. The current projected solicitation date is October of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date.